Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
第2相
完了
NCT04232280
| 対象疾患 | Cytomegalovirus Infection |
|---|
| 相 | 第2相 |
|---|
| スポンサー | ModernaTX, Inc. |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 315 名 |
|---|
| 介入（薬剤） | mRNA-1647 |
|---|
| 開始日 | 2020年1月9日 |
|---|
| 完了日 | 2023年1月4日 |
|---|
| 結果公開日 | 2026年5月5日 |
|---|
概要
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Up to Day 175 (7 days following last dose administration) · Participants
| Seronegative mRNA-1647 (50 ug) | 33 Participants |
|---|
| Seronegative mRNA-1647 (100 ug) | 59 Participants |
|---|
| Seronegative mRNA-1647 (150 ug) | 40 Participants |
|---|
| Seronegative Placebo | 12 Participants |
|---|
| Seropositive mRNA-1647 (50 ug) | 15 Participants |
|---|
| Seropositive mRNA-1647 (100 ug) | 33 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs)
Up to Day 196 (28 days following last dose administration) · Participants
| Seronegative mRNA-1647 (50 ug) | 16 Participants |
|---|
| Seronegative mRNA-1647 (100 ug) | 31 Participants |
|---|
| Seronegative mRNA-1647 (150 ug) | 18 Participants |
|---|
| Seronegative Placebo | 21 Participants |
|---|
| Seropositive mRNA-1647 (50 ug) | 10 Participants |
|---|
| Seropositive mRNA-1647 (100 ug) | 16 Participants |
|---|
Number of Participants With Medically Attended Adverse Events (MAAEs)
Up to Day 336 (6 months following last dose administration) · Participants
| Seronegative mRNA-1647 (50 ug) | 13 Participants |
|---|
| Seronegative mRNA-1647 (100 ug) | 24 Participants |
|---|
| Seronegative mRNA-1647 (150 ug) | 14 Participants |
|---|
| Seronegative Placebo | 19 Participants |
|---|
| Seropositive mRNA-1647 (50 ug) | 5 Participants |
|---|
| Seropositive mRNA-1647 (100 ug) | 11 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。